Bellerophon Therapeutics WKN: A2PZZR ISIN: US0787713009 Kürzel: BLPH Forum: Aktien Thema: Hauptdiskussion

(5) Common Stock Warrants and Warrant Liability On November 29, 2016, the Company issued 1,142,838 warrants that were immediately exercisable and will expire 5 years from issuance at an exercise price of $12.00 per share (the “2016 Warrants”). On June 28, 2019, the Company entered into a warrant amendment (the “Warrant Amendment”) with certain holders (the “Holders”) of 839,899 of the 2016 Warrants to purchase shares. Pursuant to the Warrant Amendment, the Company and the Holders agreed to eliminate provisions that had previously precluded equity classification treatment on the Company’s consolidated balance sheets. In consideration of such amendment, the 2016 Warrants were extended by two (2) additional years (until November 29, 2023). The difference in fair market value of the warrants before and after the amendment, of $0.7 million, was recorded in the consolidated statement of operations as a warrant amendment charge. The fair market value of the amended warrants was reclassified from common stock warrant liability to stockholders' equity. The balance of the 2016 Warrants that were not amended could require cash settlement under certain circumstances, and therefore continue to be classified as liabilities and to be recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of June 30, 2020, 661,310 of the 2016 Warrants were outstanding, of which 585,139 were equity classified and 76,171 were liability classified. During the six months ended June 30, 2020, 254,760 of the 2016 warrants were exercised for net proceeds of $3.1 million.      On May 15, 2017, the Company issued to an investor a warrant to purchase 66,666 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $22.50 per share. In addition, the Company issued to the placement agent warrants to purchase 4,000 shares that were immediately exercisable and will expire five years from issuance at an exercise price of $28.125 per share. As the warrants, under certain situations, could require cash settlement, the warrants were classified as liabilities and recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of June 30, 2020, all of these warrants were outstanding. On September 29, 2017, the Company issued warrants to purchase 1,296,650 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $18.63 per share. As the warrants could not require cash settlement, the warrants were classified as equity. As of June 30, 2020, all of these warrants were outstanding.

Aber nochmal Boden erstmal bei 12 13 USD (KE und Warrants)

Bello ist ein High Risk Invest. Denen fehlt halt Kohle für 2 P3. Ne gute PR wäre was....

Was meinst du bütz?

Viel risk,viel upside 😉

Scheint sich wohl alles noch etwas zu ziehen ..:

Danke!

http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-provides-clinical-program-update-and-reports-second

Leider weiter warten auf zwei Mal Phase 3. In H2 2020.

News

Covid case bin ich optimistisch!

Jap so denke ich auch bütz, hier steht sovieles an..

Es kann steigen 😎😁

Ich habe meine DD gemacht. Wenn e Inoplulse bei Covid erfolgreich eingesetzt werden kann , dann geht's hier richtig nach oben. Ansonsten down und auf den eigentlichen Case warten

Bei Novavax hats geknallt - erst nach unten und dann wieder rauf 🤷‍♂️

Es sollte bald knallen hier, das weiß auch bütz, alles andere wäre eine große Überraschung..